Pierre Fabre实验室开始试验第一阶段/第二阶段,用于MET针对NSCLC的PFL-002/VERT-002治疗。 Pierre Fabre Laboratories starts Phase I/II trial for MET-targeting NSCLC treatment PFL-002/VERT-002.

Pierre Fabre实验室已开始对PFL-002/VERT-002进行第一阶段/第二阶段临床试验,PFL-002/VERT-002是一种单克隆抗体,旨在治疗非小型细胞肺癌患者。 Pierre Fabre Laboratories has initiated a Phase I/II clinical trial for PFL-002/VERT-002, a monoclonal antibody aimed at treating non-small cell lung cancer (NSCLC) patients with MET alterations. 试验将评估治疗的安全性、可耐性和初步有效性。 The trial will evaluate the therapy's safety, tolerability, and preliminary effectiveness. 通过降解c-MET瘤基因,PFL-002/VERT-002的作用可能为对现有疗法有抗性的患者提供新的治疗选择. PFL-002/VERT-002 works by degrading the c-MET oncogene, potentially offering a new treatment option for patients resistant to existing therapies.